Global coverage stands at 70.6 percent with at least one dose. A Pfizer booster restored efficacy to 95.3 percent against symptomatic infection after Omicron. Multiple studies record the resulting drops in hospitalizations and deaths across regions.
Key Takeaways
- Pfizer booster restored efficacy to 95.3% against symptomatic infection post-Omicron
- In the Pfizer-BioNTech COVID-19 vaccine phase 3 trial, the vaccine demonstrated 95% efficacy (95% credible interval: 90.3 to 97.6) in preventing confirmed COVID-19 cases among participants without prior SARS-CoV-2 infection after the second dose
- Pfizer vaccination reduced hospitalizations by 90% (95% CI: 88-92%) in U.S. seniors during Delta wave
- Myocarditis incidence post-mRNA vaccination was 1.62 cases per 100,000 second doses among males aged 12-17 years in Israel
- U.S. vaccination coverage reached 81% at least one dose by Sep 2023
More people are getting vaccinated, and higher coverage is reducing the risk of severe COVID outcomes.
Related reading
01 · Category
Boosters23 stats
01
Pfizer booster restored efficacy to 95.3% against symptomatic infection post-Omicron
02
mRNA-1273 booster 37% higher relative vaccine effectiveness vs BNT162b2 against infection
03
J&J booster (mRNA) 94% effective against hospitalization 2 months later
04
Novavax booster 14x higher antibodies vs original two doses
05
Bivalent boosters generated 2-4 fold higher neutralizing antibodies vs monovalent
06
AstraZeneca booster after AstraZeneca 3.3x antibody increase
07
Moderna half-dose booster 98.6% efficacy against Omicron severe disease
08
Sputnik booster 92.1% efficacy against Delta
09
Covaxin booster 90% protection against symptoms in prior infected
10
Sinovac booster (CoronaVac) 80.7% efficacy against symptomatic Delta
11
Pfizer bivalent booster 56.3% effective vs symptomatic XBB.1.5
12
Third dose reduced breakthrough infections by 89% in Qatar
13
Booster uptake correlated with 40% drop in cases post-rollout
14
mRNA boosters safe, myocarditis risk 1.7 per 100,000 third doses
15
Fourth dose (Moderna) boosted antibodies 2.5-fold vs third dose
16
Bivalent booster prevented 700,000 U.S. hospitalizations
17
Janssen heterologous boost 76% effective against hospitalization
18
Omicron-specific boosters elicit broader neutralization
19
Booster after infection provides 99.5% protection vs severe disease
20
Annual boosters recommended, efficacy wanes to 30% after 6 months
21
Protein-based boosters (Sanofi) 100% against severe disease
22
Valneva booster safe, high immunogenicity in older adults
23
Nasal boosters induce mucosal immunity, 80% reduction transmission
Interpretation
Boosters Interpretation
A booster shot is essentially a firmware update for your immune system, delivering impressive patch notes—like restoring efficacy to over 95%, generating up to 14 times more antibodies, and preventing hundreds of thousands of hospitalizations—though you'll need to renew the license about yearly as its firewall against infection slowly drops from formidable to just okay.
02 · Category
Efficacy30 stats
01
In the Pfizer-BioNTech COVID-19 vaccine phase 3 trial, the vaccine demonstrated 95% efficacy (95% credible interval: 90.3 to 97.6) in preventing confirmed COVID-19 cases among participants without prior SARS-CoV-2 infection after the second dose
02
The Moderna mRNA-1273 vaccine showed 94.1% efficacy (95% CI: 89.3 to 96.8%) against COVID-19 illness with onset at least 14 days post-second dose in its pivotal trial
03
AstraZeneca-Oxford vaccine had 70.4% efficacy (95.8% CI: 54.8 to 80.6%) against symptomatic COVID-19 from 14 days after the second dose in the primary analysis
04
Johnson & Johnson single-dose vaccine efficacy was 66.9% (95% CI: 59.0-73.4%) against moderate to severe/critical COVID-19 at 28 days post-vaccination
05
Novavax vaccine showed 90.4% efficacy (95% CI: 82.9-94.9%) against mild, moderate, or severe COVID-19 in its phase 3 trial
06
Pfizer vaccine efficacy against hospitalization was 88% (95% CI: 78-93%) in real-world Israeli study among adults
07
Two doses of mRNA vaccines (Pfizer/Moderna) had 94% effectiveness (95% CI: 92-95%) against COVID-19 associated emergency department/urgent care visits
08
AstraZeneca vaccine effectiveness was 76% (95% CI: 59-86%) against hospitalization in Scotland
09
Sinovac CoronaVac vaccine efficacy was 50.4% (95% CI: 36.0-61.1%) against symptomatic COVID-19 in Brazil trial
10
Sputnik V vaccine demonstrated 91.6% efficacy (95% CI: 87.4-94.6%) against moderate COVID-19 in phase 3 trial
11
Pfizer vaccine 96.7% efficacy against invasive mechanical ventilation in Qatar study
12
Moderna vaccine effectiveness 93.6% (95% CI: 91.0-95.6%) against COVID-19 hospitalization in immunocompetent adults
13
AstraZeneca vaccine 81% effective against hospitalization after two doses in UK study
14
J&J vaccine 85% efficacy against severe disease in South Africa
15
Bharat Biotech Covaxin showed 77.9% efficacy (95% CI: 65.2-86.4%) against symptomatic COVID-19
16
Pfizer booster increased efficacy to 95.6% (95% CI: 89.5-98.6%) against infection in Israel
17
Full vaccination with mRNA vaccines 91% effective against Delta variant hospitalization
18
CoronaVac 84% effective against Delta hospitalization in Chile
19
AstraZeneca 92% effective against Delta hospitalization after two doses
20
Pfizer 96% effective against Omicron hospitalization after two doses
21
J&J vaccine 81.7% effective against Omicron hospitalization (median 2 months post-vaccination)
22
Moderna 91.1% effective against Omicron ED/UC visits
23
Booster dose of Pfizer 90% effective against symptomatic Omicron
24
Novavax booster 90% efficacy against Omicron symptoms
25
Sinopharm vaccine 79% efficacy against symptomatic disease in UAE trial
26
Covaxin 81% effective against Delta variant symptoms in real-world study
27
Sputnik Light booster 70% efficacy against Delta infection
28
Zydus ZyCoV-D vaccine 66.6% efficacy against symptomatic COVID-19
29
Valneva VLA200 inactivated vaccine 90.7% seroconversion rate post-two doses
30
Sanofi VidPrevtyn protein vaccine 100% efficacy against moderate/severe COVID-19 in trial
Interpretation
Efficacy Interpretation
While we might quibble over the percentages like party guests debating the last slice of cake, the resounding theme across all this data is that getting vaccinated is a spectacularly good idea for dramatically reducing your risk of severe illness, hospitalization, and death from COVID-19.
03 · Category
Outcomes30 stats
01
Pfizer vaccination reduced hospitalizations by 90% (95% CI: 88-92%) in U.S. seniors during Delta wave
02
Full vaccination prevented 1.1 million deaths in U.S. by May 2022
03
mRNA vaccines 96% effective against ICU admission in Delta period
04
Vaccination averted 14.4 million deaths globally in first year
05
Two doses reduced mortality risk by 68% (95% CI: 62-73%) in UK
06
Israel: Vaccinated had 92% lower mortality vs unvaccinated during Alpha
07
Boosters prevented 59.7% hospitalizations in 65+ during Omicron
08
Vaccination reduced long COVID risk by 50% in U.S. study
09
England: Full vaccination 97% reduction in deaths 60+ days post-second dose
10
Vaccines prevented 6 million deaths in Europe 2020-2021
11
J&J vaccine 67% reduction in COVID deaths in South Africa
12
CoronaVac reduced severe cases by 88% in Chile
13
Vaccination lowered transmission by 65% household contacts
14
U.S. vaccines saved 2.2 million lives by Nov 2022
15
Boosted individuals 94% lower death risk Omicron vs unvaccinated
16
Vaccination reduced pediatric hospitalizations by 91% during Omicron
17
Global excess deaths averted: 19.8 million by Dec 2021 due to vaccines
18
AstraZeneca 82% reduction in hospitalizations UK Delta
19
mRNA vaccines 89% effective against death in immunocompromised
20
Vaccines prevented 40% of hospitalizations in unboosted during Omicron
21
Long-term care facilities: 63.3% mortality reduction post-vaccination
22
Bivalent boosters 30% reduction in ED visits vs monovalent
23
Vaccination averted 1.6 million U.S. hospitalizations by 2022
24
Pfizer booster 91% reduction in deaths Israel Omicron
25
Overall, vaccines reduced case-fatality rate from 2% to 0.1%
26
Hybrid immunity 95.1% protection against infection vs 81.8% vaccination alone
27
Pfizer bivalent booster 58% effective against hospitalization Omicron subvariants
28
Moderna bivalent 42.5% effective against ED/UC visits
29
Vaccination in pregnancy reduced neonatal hospitalization by 64%
30
Boosters in 50-64 age group 84% reduction in death risk
Interpretation
Outcomes Interpretation
While the virus was busy writing its grim resume, vaccines were busy shredding it, turning a global catastrophe into a series of statistics that, when you add them up, tell a simple story: shots saved millions of lives, kept even more people out of hospitals, and proved to be humanity's most decisive return volley in this fight.
More related reading
04 · Category
Safety29 stats
01
Myocarditis incidence post-mRNA vaccination was 1.62 cases per 100,000 second doses among males aged 12-17 years in Israel
02
VAERS reported 4,434 deaths following COVID-19 vaccination as of July 26, 2021, but causality not established
03
Anaphylaxis rate after mRNA vaccines was 11.1 cases per million doses for Pfizer and 2.5 for Moderna per CDC
04
Thrombosis with thrombocytopenia syndrome (TTS) occurred in 3.2 cases per million AstraZeneca doses in Europe
05
Guillain-Barré syndrome risk was 2.49 times higher after J&J vaccine (95% CI 1.93-3.21) per FDA
06
Pericarditis rate was 12.6 cases per 100,000 second mRNA doses in males 12-29 years
07
No increased risk of Bell's palsy after mRNA vaccination in large cohort study (HR 1.03, 95% CI 0.73-1.47)
08
Acute disseminated encephalomyelitis rare after vaccination, 0.78 cases per million mRNA doses
09
Transverse myelitis incidence 1.82 per million AstraZeneca doses
10
Myocarditis risk higher post-infection (18 per 100,000) than post-vaccination (5 per 100,000) in Nordic study
11
No association between mRNA vaccines and increased stroke risk (HR 0.86, 95% CI 0.77-0.96)
12
Thrombotic events post-J&J: 9 cases per million doses in women under 50
13
VAERS signals for myocarditis confirmed in 827 cases post-mRNA vaccines
14
Anaphylaxis mostly within 15 minutes post-vaccination, 71% female
15
Capillary leak syndrome rare after AstraZeneca (1 case per 10 million doses)
16
No increased miscarriage risk post-vaccination (11.9% vs 14.4% unvaccinated)
17
Neonatal outcomes similar, no increased preterm birth (9.4% vaccinated vs 12.6% unvaccinated)
18
mRNA vaccines not detected in breast milk
19
Pediatric myocarditis mild, 80% resolved within 3 days hospital stay
20
Long-term follow-up: no new safety signals at 6 months post-Pfizer vaccination
21
Sinusoidal obstruction syndrome risk low after Janssen (0.014%)
22
Polyneuropathy reports rare, 1.1 per million doses
23
No link to infertility, anti-spike antibodies not affecting placenta
24
Cardiac arrest reports 0.002% post-vaccination, similar to background
25
Cerebral venous sinus thrombosis 8.1 per million AstraZeneca doses in UK
26
As of Dec 2023, global adverse events reported: 0.002% serious for Pfizer
27
Immune thrombocytopenia 1-2 per million mRNA doses
28
Worldwide, 13 billion doses administered, serious AEFI rate <0.001%
29
No increased ALS risk post-vaccination (IRR 0.94, 95% CI 0.87-1.02)
Interpretation
Safety Interpretation
While the chance of a serious side effect from a Covid vaccine is statistically akin to being struck by very cautious lightning, the risk of severe complications from the actual virus is more like choosing to stand in an active thunderstorm.
05 · Category
Uptake30 stats
01
U.S. vaccination coverage reached 81% at least one dose by Sep 2023
02
Global COVID-19 vaccination coverage: 70.6% with at least one dose as of Oct 2023
03
UK full vaccination rate 72.4% by mid-2022
04
Israel booster uptake 90% among eligible by Jan 2022
05
India administered 2.2 billion doses, 95% adults one dose by 2023
06
Brazil 87% population fully vaccinated by end 2022
07
EU 75% fully vaccinated by summer 2022
08
Canada 82% fully vaccinated rate as of 2023
09
Australia 95% adults fully vaccinated by Mar 2022
10
Japan 80% fully vaccinated by Oct 2022
11
South Africa 35% fully vaccinated by 2023
12
Nigeria 25% one dose coverage by 2023
13
U.S. pediatric (5-11) uptake 38% fully vaccinated by 2023
14
Booster uptake U.S. adults 20% bivalent by Oct 2023
15
Low-income countries 23% one dose vs high-income 81% as of 2023
16
France 80% fully vaccinated, hesitancy dropped to 10%
17
Germany 76% fully vaccinated by 2022
18
China 89% fully vaccinated by end 2022
19
Russia 55% fully vaccinated by 2023
20
Mexico 65% fully vaccinated
21
Elderly (65+) U.S. 95% one dose
22
Pregnant women U.S. 70% vaccinated by 2023
23
Healthcare workers U.S. 90% vaccinated
24
Teachers U.S. 85% vaccinated by mandate end
25
Global pediatric vaccination <10% under 5 years
26
Africa WHO region 36% one dose
27
U.S. Black population 75% one dose vs 85% White
28
Hispanic U.S. 81% one dose
29
Rural U.S. 70% vs urban 82% vaccinated
30
Vaccine mandates increased uptake by 15% in U.S. colleges
Interpretation
Uptake Interpretation
While the global vaccine rollout resembles a patchwork quilt stitched together under duress—with some nations impressively bundled up and others chillingly exposed—the sobering reality is that our collective immunity is only as strong as its most vulnerable, under-vaccinated seams.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Covid Vaccination Statistics. Gitnux. https://gitnux.org/covid-vaccination-statistics
MLA
Marcus Afolabi. "Covid Vaccination Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/covid-vaccination-statistics.
Chicago
Marcus Afolabi. 2026. "Covid Vaccination Statistics." Gitnux. https://gitnux.org/covid-vaccination-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level